CVS vs. ELV: Which Healthcare Titan Is the Stronger Investment Today?

CVS Health reported Q2 2025 revenue growth across all segments, is actively restoring Aetna's target margins, and plans significant investments in digital health while targeting $500 million in cost savings for 2025, contributing to its 59.4% year-to-date share rally and a projected 16.6% EPS growth for 2025. In contrast, Elevance Health's 2025 adjusted EPS forecast was cut to $30 from a prior range of $34.15-$34.85 due to ongoing ACA and Medicaid market pressures, leading to a 15.9% year-to-date share decline and an anticipated 8.8% EPS decrease, positioning CVS as the stronger investment.

Analysis

CVS Health and Elevance Health are on diverging operational and financial trajectories. CVS is demonstrating broad-based strength, reporting revenue growth across all segments in Q2 2025 and executing on a multi-pronged strategy that includes restoring Aetna's target margins, a $500 million cost-saving initiative for 2025, and a $20 billion long-term investment in digital health. Strategically, CVS is optimizing its portfolio by exiting the underperforming individual ACA exchange business and acquiring Rite Aid assets, which is expected to bolster its retail segment. This positive momentum is reflected in its stock performance, with a 59.4% year-to-date rally, a projected 16.6% EPS growth for 2025, and a favorable valuation with a forward price-to-sales multiple of 0.23X. In stark contrast, Elevance Health is grappling with significant headwinds in its Medicaid and ACA businesses, stemming from membership shifts and higher member acuity that have elevated medical costs. This resulted in a 260 basis point year-over-year increase in its benefit expense ratio to 88.9% and a substantial cut in its full-year adjusted EPS forecast to approximately $30. The negative outlook is further confirmed by an 8.8% projected EPS decline for 2025 and a 12.4% downward revision in analyst estimates over the past 90 days, contributing to the stock's 15.9% year-to-date loss.

Key Decisions for Investors

• Given its strong cross-segment revenue growth, strategic restructuring yielding over $500 million in expected savings, and a projected 16.6% EPS growth, CVS presents a compelling investment case, further supported by its discounted valuation relative to the industry.
• Investors should exercise caution with Elevance Health due to its significant 2025 EPS guidance reduction, persistent margin compression from its core Medicaid and ACA businesses, and the 15.9% year-to-date decline in its share price, which all signal continued fundamental challenges.
• The contrasting performance creates a potential relative value opportunity; however, investors should closely monitor the execution of CVS's Aetna margin restoration against any signs of stabilization in Elevance's benefit expense ratio, as these are the primary catalysts for their respective stock narratives.